THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.14] ID: TIP-MED-000142

Acyclovir (Aciclovir) (and Valacyclovir comparison)

Active Ingredient / Scientific Identity: Acyclovir • Class: Synthetic Purine Nucleoside Analogue Antiviral (Activated by Viral Thymidine Kinase to Inhibit Herpesvirus DNA Polymerase)

⚖️ Compare Profile
Generic / Entity NameAcyclovir (Aciclovir) (and Valacyclovir comparison) ([8.14])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSynthetic Purine Nucleoside Analogue Antiviral (Activated by Viral Thymidine Kinase to Inh
Available Dosage FormsOral Uncoated / Dispersible Tablets: 200 mg, 400 mg, 800 mg; Oral Suspension: 200 mg/5 mL, 400 mg/5 mL; Topica
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 65–90% unchanged in urine; t1/2 jumps from 2.5 h to 20 h in renal failure)
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Acyclovir (Aciclovir) (and Valacyclovir comparison) (TIP-MED-000142, Reference Code [8.14]) is classified under Antimicrobials — Antiviral & Antiretroviral Agents (Ch 08) as a Synthetic Purine Nucleoside Analogue Antiviral (Activated by Viral Thymidine Kinase to Inhibit Herpesvirus DNA Polymerase). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.14], p. 99): Zovirax (GSK), Acivir (Cipla), Herpex (Torrent), Ocuvir (FDC Ltd); Note: Valacyclovir (Valcivir [Cipla], Zimivir [GSK]—500 mg, 1000 mg) is the L-valyl ester prodrug of Acyclovir with 3- to 5-fold higher oral bioavailability, allowing TDS instead of 5x/day dosing! — Strengths & Dosage Forms: Oral Uncoated / Dispersible Tablets: 200 mg, 400 mg, 800 mg; Oral Suspension: 200 mg/5 mL, 400 mg/5 mL; Topical Cream: 5% w/w; Ophthalmic Ointment: 3% w/w; IV Infusion: 250 mg, 500 mg vials
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.14], p. 99): Zovirax (GSK), Acivir (Cipla), Herpex (Torrent), Ocuvir (FDC Ltd); Note: Valacyclovir (Valcivir [Cipla], Zimivir [GSK]—500 mg, 1000 mg) is the L-valyl ester prodrug of Acyclovir with 3- to 5-fold higher oral bioavailability, allowing TDS instead of 5x/day dosing! — Strengths & Dosage Forms: Oral Uncoated / Dispersible Tablets: 200 mg, 400 mg, 800 mg; Oral Suspension: 200 mg/5 mL, 400 mg/5 mL; Topical Cream: 5% w/w; Ophthalmic Ointment: 3% w/w; IV Infusion: 250 mg, 500 mg vials
Dosage Forms & Available Strengths:
Oral Uncoated / Dispersible Tablets: 200 mg, 400 mg, 800 mg; Oral Suspension: 200 mg/5 mL, 400 mg/5 mL; Topical Cream: 5% w/w; Ophthalmic Ointment: 3% w/w; IV Infusion: 250 mg, 500 mg vials
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Synthetic Purine Nucleoside Analogue Antiviral (Activated by Viral Thymidine Kinase to Inhibit Herpesvirus DNA Polymerase) acting on target receptor/enzyme pathways in Antimicrobials — Antiviral & Antiretroviral Agents (Ch 08): clinical efficacy is mediated via Synthetic Purine Nucleoside Analogue Antiviral (Activated by Viral Thymidine Kinase to Inhibit Herpesvirus DNA Polymerase) for Herpes Zoster (Shingles—requires high-dose 800 mg 5 times daily!) and Varicella (Chickenpox); mucocutaneous and genital Herpes Simplex Virus (HSV-1 and HSV-2) treatment and suppression; HSV keratitis (3% eye ointment) and HSV encephalitis (IV)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Herpes Zoster (Shingles—requires high-dose 800 mg 5 times daily!) and Varicella (Chickenpox)
  • mucocutaneous and genital Herpes Simplex Virus (HSV-1 and HSV-2) treatment and suppression
  • HSV keratitis (3% eye ointment) and HSV encephalitis (IV)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Highly Indication-Dependent (Oral bioavailability of plain Acyclovir is only 15–20%): • Herpes Zoster (Shingles) / Adult Varicella: 800 mg FIVE times daily (every 4 hours while awake: e.g., 07:00, 11:00, 15:00, 19:00, 23:00—skipping the 03:00 AM night dose) for 7 to 10 days! (Or Valacyclovir 1000 mg three times daily for 7 days). • Acute Genital / Mucocutaneous HSV: 400 mg three times daily (or 200 mg 5 times daily) for 5 to 10 days. • Dosing strictly depends on renal CrCl! Follow physician prescription.

Administration & Meal Timing: With or without food, accompanied by a FULL GLASS OF WATER with every single tablet! | 5 times daily (every 4 hours while awake: 7 AM, 11 AM, 3 PM, 7 PM, 11 PM) for Shingles; 3 times daily (every 8 hours) for HSV.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 65–90% unchanged in urine; t1/2 jumps from 2.5 h to 20 h in renal failure)! For Herpes Zoster (800 mg regimen): • CrCl >25 mL/min: 800 mg every 4 hours (5 times daily). • CrCl 10–25 mL/min: 800 mg THREE times daily (every 8 hours)! • CrCl <10 mL/min: 800 mg TWICE daily (every 12 hours)! (Similarly, for Valacyclovir in Zoster: CrCl ≥50: 1000 mg TDS; CrCl 30–49: 1000 mg BD; CrCl 10–29: 1000 mg OD; CrCl <10: 500 mg OD). Hepatic: No dose adjustment needed.
Elimination & Renal Adjustment:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 65–90% unchanged in urine; t1/2 jumps from 2.5 h to 20 h in renal failure)! For Herpes Zoster (800 mg regimen): • CrCl >25 mL/min: 800 mg every 4 hours (5 times daily). • CrCl 10–25 mL/min: 800 mg THREE times daily (every 8 hours)! • CrCl <10 mL/min: 800 mg TWICE daily (every 12 hours)! (Similarly, for Valacyclovir in Zoster: CrCl ≥50: 1000 mg TDS; CrCl 30–49: 1000 mg BD; CrCl 10–29: 1000 mg OD; CrCl <10: 500 mg OD). Hepatic: No dose adjustment needed.
Hepatic Impairment Considerations:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 65–90% unchanged in urine; t1/2 jumps from 2.5 h to 20 h in renal failure)! For Herpes Zoster (800 mg regimen): • CrCl >25 mL/min: 800 mg every 4 hours (5 times daily). • CrCl 10–25 mL/min: 800 mg THREE times daily (every 8 hours)! • CrCl <10 mL/min: 800 mg TWICE daily (every 12 hours)! (Similarly, for Valacyclovir in Zoster: CrCl ≥50: 1000 mg TDS; CrCl 30–49: 1000 mg BD; CrCl 10–29: 1000 mg OD; CrCl <10: 500 mg OD). Hepatic: No dose adjustment needed.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • 1. Crystal-Induced Obstructive Acute Kidney Injury (Crystalluria): Acyclovir has low solubility in urine; high doses (800 mg 5x/day or rapid IV infusion) in dehydrated or elderly patients precipitate as needle-shaped crystals inside renal tubules! 2. Acyclovir Neurotoxicity in Renal Impairment: Unadjusted doses in CKD cause acute encephalopathy!

Key Clinical Precautions: Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 65–90% unchanged in urine; t1/2 jumps from 2.5 h to 20 h in renal failure)! For Herpes Zoster (800 mg regimen): • CrCl >25 mL/min: 800 mg every 4 hours (5 times daily). • CrCl 10–25 mL/min: 800 mg THREE times daily (every 8 hours)! • CrCl <10 mL/min: 800 mg TWICE daily (every 12 hours)! (Similarly, for Valacyclovir in Zoster: CrCl ≥50: 1000 mg TDS; CrCl 30–49: 1000 mg BD; CrCl 10–29: 1000 mg OD; CrCl <10: 500 mg OD). Hepatic: No dose adjustment needed.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea, headache, mild diarrhoea, malaise, local stinging with topical/ophthalmic application.
  • Crystal-induced Acute Kidney Injury / Obstructive Nephropathy, Acyclovir/Valacyclovir Neurotoxicity (occurs within 24–72 hours in elderly patients with reduced eGFR: confusion, agitation, dysarthria, visual hallucinations, myoclonus, ataxia, and coma—often misdiagnosed as Herpes Zoster encephalitis!), thrombotic thrombocytopenic purpura (high-dose in immunocompromised).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Nephrotoxic Drugs (NSAIDs like diclofenac/ibuprofen, aminoglycosides, cyclosporine, tenofovir) markedly increase the risk of acyclovir crystal nephropathy and neurotoxicity! Probenecid, cimetidine, and mycophenolate mofetil compete for renal tubular OAT secretion, increasing plasma acyclovir levels

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: When dispensing Acivir 800 DT / Zovirax 800 for Shingles (Herpes Zoster): 1. Write out the exact 5-times-daily clock schedule (7 AM, 11 AM, 3 PM, 7 PM, 11 PM) so the patient does not wake up at 3 AM. 2. Dispersible tablets (Acivir 800 DT) can be dispersed in 50 mL of water or swallowed whole with a full glass of water. 3. Insist on drinking at least 8–10 glasses of water daily to protect the kidneys. 4. Tell family caregivers to report immediately if the elderly patient becomes confused, drowsy, or starts seeing things (hallucinations), as that means the antiviral dose is too high for their kidneys.
  • Meal & Clock Timing Instruction: With or without food, accompanied by a FULL GLASS OF WATER with every single tablet! (5 times daily (every 4 hours while awake: 7 AM, 11 AM, 3 PM, 7 PM, 11 PM) for Shingles; 3 times daily (every 8 hours) for HSV.)
  • Missed Dose Protocol: Take as soon as remembered with a full glass of water; never double the dose.
  • Geriatric Dispensing Pearl: Herpes Zoster (Shingles) is overwhelmingly a disease of elderly and diabetic CGHS patients. Always calculate CrCl before dispensing 800 mg 5x/day Acyclovir or 1000 mg TDS Valacyclovir to a patient >70 years, and avoid co-prescribing NSAIDs (use Paracetamol + low-dose Pregabalin/Gabapentin for acute zoster pain instead, so NSAIDs do not precipitate acyclovir renal failure!).

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated / Dispersible Tablets: 200 mg, 400 mg, 800 mg; Oral Suspension: 200 mg/5 mL, 400 mg/5 mL; Topical Cream: 5% w/w; Ophthalmic Ointment: 3% w/w; IV Infusion: 250 mg, 500 mg vials

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.14] (p. 99)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.